Upstream Competitors
| UPB Stock | 26.20 0.20 0.77% |
Upstream Bio vs Spyre Therapeutics Correlation
Poor diversification
The correlation between Upstream Bio and SYRE is 0.79 (i.e., Poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Upstream Bio and SYRE in the same portfolio, assuming nothing else is changed.
Moving together with Upstream Stock
Moving against Upstream Stock
| 0.73 | EVGN | Evogene | PairCorr |
| 0.7 | GNLX | Genelux Common | PairCorr |
| 0.67 | LYRA | Lyra Therapeutics | PairCorr |
| 0.57 | IMRN | Immuron Ltd ADR | PairCorr |
| 0.56 | DWTX | Dogwood Therapeutics | PairCorr |
Upstream Bio Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Upstream Bio and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Upstream and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Upstream Bio does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Upstream Stock performing well and Upstream Bio Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Upstream Bio's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ZBIO | 5.55 | 0.08 | 0.00 | 0.02 | 0.00 | 9.05 | 68.95 | |||
| NTLA | 4.31 | (0.16) | 0.00 | 0.02 | 6.05 | 10.73 | 33.96 | |||
| WVE | 6.08 | 1.86 | 0.33 | (0.79) | 4.09 | 6.72 | 164.47 | |||
| RLAY | 3.22 | 0.41 | 0.11 | 0.59 | 3.35 | 6.40 | 30.68 | |||
| PHVS | 3.29 | 0.32 | 0.05 | (0.59) | 3.59 | 6.58 | 27.81 | |||
| SNDX | 2.84 | 0.63 | 0.28 | 0.81 | 1.93 | 8.70 | 18.37 | |||
| NVAX | 3.05 | 0.00 | 0.02 | 0.08 | 3.14 | 6.10 | 26.98 | |||
| AMLX | 3.12 | 0.12 | 0.01 | 4.13 | 3.36 | 8.11 | 22.15 | |||
| TERN | 4.44 | 1.74 | 0.51 | (3.38) | 2.49 | 8.83 | 43.41 | |||
| SYRE | 2.68 | 0.54 | 0.20 | 0.48 | 2.48 | 7.15 | 20.03 |
Cross Equities Net Income Analysis
Compare Upstream Bio and related stocks such as Zenas BioPharma Common, Intellia Therapeutics, and Wave Life Sciences Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NTLA | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (12.4 M) | (31.6 M) | (67.5 M) | (85.3 M) | (99.5 M) | (125.6 M) | (259.7 M) | (474.2 M) | (481.2 M) | (519 M) | (467.1 M) | (443.8 M) |
| WVE | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (5.2 M) | (19.2 M) | (55.4 M) | (102 M) | (146.7 M) | (193.6 M) | (149.9 M) | (122.2 M) | (161.8 M) | (57.5 M) | (97 M) | (87.3 M) | (91.7 M) |
| RLAY | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (66.5 M) | (52.4 M) | (363.9 M) | (290.5 M) | (342 M) | (337.7 M) | (303.9 M) | (319.1 M) |
| PHVS | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (9 M) | (29.6 M) | (42.7 M) | (76.3 M) | (100.9 M) | (134.2 M) | (120.8 M) | (114.8 M) |
| SNDX | (13.1 M) | (13.1 M) | (10 M) | (14.2 M) | (19.8 M) | (24.1 M) | (44.5 M) | (60.8 M) | (74 M) | (56 M) | (73.1 M) | 24.9 M | (143.7 M) | (209.4 M) | (318.8 M) | (286.9 M) | (272.5 M) |
| NVAX | (5.5 M) | (19.4 M) | (28.5 M) | (52 M) | (82.9 M) | (156.9 M) | (280 M) | (183.8 M) | (184.7 M) | (130.1 M) | (427.5 M) | (1.7 B) | (657.9 M) | (545.1 M) | (187.5 M) | (168.7 M) | (177.2 M) |
| TERN | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (68.8 M) | (29.4 M) | (50.2 M) | (60.3 M) | (90.2 M) | (88.9 M) | (80 M) | (84 M) |
| SYRE | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (11.3 M) | (21.7 M) | (27.2 M) | (44.3 M) | (78.3 M) | (80.9 M) | (65.8 M) | (83.8 M) | (338.8 M) | (208 M) | (187.2 M) | (177.9 M) |
Upstream Bio and related stocks such as Zenas BioPharma Common, Intellia Therapeutics, and Wave Life Sciences Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Upstream Bio financial statement analysis. It represents the amount of money remaining after all of Upstream Bio operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Upstream Bio Competitive Analysis
The better you understand Upstream Bio competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Upstream Bio's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Upstream Bio's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Upstream Bio Competition Performance Charts
Five steps to successful analysis of Upstream Bio Competition
Upstream Bio's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Upstream Bio in relation to its competition. Upstream Bio's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Upstream Bio in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Upstream Bio's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Upstream Bio, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Upstream Bio position
In addition to having Upstream Bio in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Obamacare Thematic Idea Now
Obamacare
Health care services and providers including hospitals, clinics and nursing homes that hope to benefit from Obamacare program. The Obamacare theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Obamacare Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Upstream Bio Correlation with its peers. For information on how to trade Upstream Stock refer to our How to Trade Upstream Stock guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Upstream Bio. If investors know Upstream will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Upstream Bio assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (6.40) | Revenue Per Share | Quarterly Revenue Growth 0.125 | Return On Assets | Return On Equity |
The market value of Upstream Bio is measured differently than its book value, which is the value of Upstream that is recorded on the company's balance sheet. Investors also form their own opinion of Upstream Bio's value that differs from its market value or its book value, called intrinsic value, which is Upstream Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Upstream Bio's market value can be influenced by many factors that don't directly affect Upstream Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Upstream Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Upstream Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Upstream Bio's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.